Research ArticleArticle
CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes
Mats Hidestrand, Mikael Oscarson, Jarmo S. Salonen, Leena Nyman, Olavi Pelkonen, Miia Turpeinen and Magnus Ingelman-Sundberg
Drug Metabolism and Disposition November 2001, 29 (11) 1480-1484;
Mats Hidestrand
Mikael Oscarson
Jarmo S. Salonen
Leena Nyman
Olavi Pelkonen
Miia Turpeinen
Magnus Ingelman-Sundberg

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Drug Metabolism and Disposition
Vol. 29, Issue 11
1 Nov 2001
Research ArticleArticle
CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes
Mats Hidestrand, Mikael Oscarson, Jarmo S. Salonen, Leena Nyman, Olavi Pelkonen, Miia Turpeinen and Magnus Ingelman-Sundberg
Drug Metabolism and Disposition November 1, 2001, 29 (11) 1480-1484;
Research ArticleArticle
CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes
Mats Hidestrand, Mikael Oscarson, Jarmo S. Salonen, Leena Nyman, Olavi Pelkonen, Miia Turpeinen and Magnus Ingelman-Sundberg
Drug Metabolism and Disposition November 1, 2001, 29 (11) 1480-1484;
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement